Insider

Regeneron received $1.0 billion upfront payment and may receive up to $7.0 billion under a new deal with Sanofi

Regeneron signed the Sixth Amendment to its Sanofi agreement, received a $1.0 billion upfront and may earn up to $7.0 billion on milestone achievement; it also disclosed a $22 million charge that will lower earnings per share (EPS) by about $0.18.

Verified against 1 archived primary source · SHA-256 recorded Inspect sources & citations ↓
A scientist in a white lab coat using a laptop in a laboratory
Photo by ThisisEngineering on Unsplash

Key points

  • The Sixth Amendment provides for joint development and commercialization of four new long‑acting antibodies, with Sanofi paying Regeneron a $1.0 billion upfront and committing up to $7.0 billion in additional payments upon milestone attainment.
  • The $1.0 billion upfront improves Regeneron’s liquidity, while the potential $7.0 billion in extra payments could substantially boost future cash inflows if the development, regulatory and commercial milestones are met.
  • Regeneron is the lead developer and regulatory partner in the United States, with Sanofi handling the rest of the world; successful approvals and sales would allow Regeneron to receive its share of payments and split global profit equally with Sanofi, creating additional revenue for shareholders.

What happened

The Sixth Amendment provides for joint development and commercialization of four new long‑acting antibodies, with Sanofi paying Regeneron a $1.0 billion upfront and committing up to $7.0 billion in additional payments upon milestone attainment.

The companies also entered a settlement that resolves a dispute over Regeneron’s access to material information about Dupixent commercialization and audit rights.

Regeneron said it will record $22 million of research and development expense (pre‑tax), which it estimates will cut EPS by roughly $0.18.

Why it matters

The $1.0 billion upfront improves Regeneron’s liquidity, while the potential $7.0 billion in extra payments could substantially boost future cash inflows if the development, regulatory and commercial milestones are met.

$22 million of GAAP – generally accepted accounting principles – and non‑GAAP expenses will reduce net income per share, which will appear in Regeneron’s third‑quarter 2026 report.

When it could profit shareholders

Regeneron is the lead developer and regulatory partner in the United States, with Sanofi handling the rest of the world; successful approvals and sales would allow Regeneron to receive its share of payments and split global profit equally with Sanofi, creating additional revenue for shareholders.

Risks and uncertainties

The $22 million expense could lower EPS, and successful development, approval and commercialization of the new antibodies is not guaranteed; failure at any stage would deprive Regeneron of a portion of the $7.0 billion bonus payments.

What to watch

Investors should monitor announcements of milestone achievements, FDA filing and approval updates, and the third‑quarter 2026 report, which will show the impact of the $22 million expense and assess potential payments.

Original sources

  1. 8-K filing, October 6, 2026October 6, 2026SHA-256 of our archived copy e7faa8e63bec…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards